Construct validity of PROMIS pain interference, fatigue, and physical function as patient-reported outcomes in adults with idiopathic inflammatory myopathies: An international study from the OMERACT myositis working group
Authors' conclusion
PROMIS Short Form v1.0-Pain Interference 6a, PROMIS Short Form v1.0-Fatigue 7a, and PROMIS Short Form v2.0-Physical Function 8b measures demonstrate strong construct validity when compared to core disease activity measures in IIM, with consistent results across IIM subtypes.
Study context
- Population
- Adults with IIM, excluding inclusion body myositis, from OMERACT Myositis Working Group (MWG) clinic sites in 5 countries across North America, Europe, Asia and Australia
- Participants
- 135 adults5 countries
- Exposure
- PROMIS Pain Interference, Fatigue and Physical Function vs core disease activity measures
- Dermatomyositisn = 65
- Non-dermatomyositisn = 70
- Outcome
- Construct validity: a priori hypothesised correlations between PROMIS measures, age and core disease measures vs observed Pearson's correlations
Methodological detailsmulticentre, international, construct validity, a priori hypotheses
- Multicentre
- International
- Construct validity
- A priori hypotheses
Main finding
As reported in the abstract
A priori hypotheses confirmed (construct validity)
PROMIS Pain Interference correlations confirmed
5 of 6
83 %
PROMIS Fatigue correlations confirmed
4 of 5
80 %
PROMIS Physical Function correlations confirmed
3 of 4
75 %
Observational data: associations, not effects.
Further findings
Internal consistency
- Cronbach's alpha, each PROMIS measure (high)
- >0.9
Ceiling effects
- Only PROMIS Pain Interference: low/no pain
- 29 %
Correlations by IIM subtype (subgroup)
- Similar correlations between PROMIS measures and disease activity measures in dermatomyositis and non-dermatomyositis
Original publication
Construct validity of PROMIS pain interference, fatigue, and physical function as patient-reported outcomes in adults with idiopathic inflammatory myopathies: An international study from the OMERACT myositis working group. Semin Arthritis Rheum. Published 10 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →